英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
newlylevied查看　newlylevied　在百度字典中的解释百度英翻中〔查看〕
newlylevied查看　newlylevied　在Google字典中的解释Google英翻中〔查看〕
newlylevied查看　newlylevied　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Investors | MacroGenics, Inc.
    The Investor Relations website contains information about MacroGenics, Inc 's business for stockholders, potential investors, and financial analysts
  • Press Releases - MacroGenics, Inc.
    The Investor Relations website contains information about MacroGenics, Inc 's business for stockholders, potential investors, and financial analysts
  • Events Presentations | MacroGenics, Inc.
    The Investor Relations website contains information about MacroGenics, Inc 's business for stockholders, potential investors, and financial analysts
  • Quarterly Results - MacroGenics, Inc.
    The Investor Relations website contains information about MacroGenics, Inc 's business for stockholders, potential investors, and financial analysts
  • 1904 Exatecan-based Antibody-drug Conjugate (ADC) Targeting B7-H3 for . . .
    Abstract Introduction: Antibody-drug conjugates (ADCs) have emerged as an important class of therapeutic agents for the treatment of cancer A duocarmycin-based B7-H3-targeted DNA-alkylating ADC, vobramitamab duocarmazine (vobra duo), has shown encouraging clinical activity in the treatment of metastatic castration-resistant prostate cancer Given the broad spectrum of tumor indications
  • MacroGenics Announces Leadership Transition
    MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer
  • MacroGenics Announces Date of Fourth Quarter and Full Year 2024 . . .
    ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday
  • MacroGenics to Present at H. C. Wainwright 27th Annual Global Investment . . .
    ROCKVILLE, MD, Sept 02, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President Chief Executive Officer, Eric Risser, will present at the H C Wainwright 27 th Annual Global Investment Conference on Monday, September 8, 2025
  • MacroGenics Announces Presentations at ESMO 2021 Virtual Annual . . .
    ROCKVILLE, MD, Sept 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) Virtual Conference
  • MacroGenics to Participate in Upcoming Investor Conferences
    The Investor Relations website contains information about MacroGenics, Inc 's business for stockholders, potential investors, and financial analysts





中文字典-英文字典  2005-2009